Year All2024202320222021202020192018201720162014201320112010 July 1, 2020 Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities June 24, 2020 Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers May 26, 2020 Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in June May 13, 2020 Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities May 5, 2020 Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference May 4, 2020 Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results April 7, 2020 Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference March 30, 2020 Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations March 30, 2020 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities March 18, 2020 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome
July 1, 2020 Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities
June 24, 2020 Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers
May 13, 2020 Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities
May 5, 2020 Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference
April 7, 2020 Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference
March 30, 2020 Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations
March 30, 2020 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
March 18, 2020 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome
